-
Something wrong with this record ?
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
J. Butler, SJ. Shah, MC. Petrie, BA. Borlaug, SZ. Abildstrøm, MJ. Davies, GK. Hovingh, DW. Kitzman, DV. Møller, S. Verma, MN. Einfeldt, ML. Lindegaard, S. Rasmussen, W. Abhayaratna, FZ. Ahmed, T. Ben-Gal, V. Chopra, JA. Ezekowitz, M. Fu, H. Ito,...
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Randomized Controlled Trial
Grant support
R01 HL140731
NHLBI NIH HHS - United States
R01 HL127028
NHLBI NIH HHS - United States
R01 HL107577
NHLBI NIH HHS - United States
R01 HL149423
NHLBI NIH HHS - United States
U54 HL160273
NHLBI NIH HHS - United States
NLK
ProQuest Central
from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest)
from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest)
from 1992-01-04 to 3 months ago
Family Health Database (ProQuest)
from 1992-01-04 to 3 months ago
Psychology Database (ProQuest)
from 1992-01-04 to 3 months ago
Health Management Database (ProQuest)
from 1992-01-04 to 3 months ago
Public Health Database (ProQuest)
from 1992-01-04 to 3 months ago
- MeSH
- Double-Blind Method MeSH
- Glucagon-Like Peptides * therapeutic use administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Obesity * complications drug therapy MeSH
- Randomized Controlled Trials as Topic MeSH
- Aged MeSH
- Heart Failure * drug therapy MeSH
- Stroke Volume * drug effects MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction. In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, we aimed to provide a more definitive assessment of the effects of semaglutide across a range of outcomes and to test whether these effects were consistent across key patient subgroups. METHODS: We conducted a prespecified pooled analysis of individual patient data from STEP-HFpEF and STEP-HFpEF DM, randomised, double-blind, placebo-controlled trials at 129 clinical research sites in 18 countries. In both trials, eligible participants were aged 18 years or older, had heart failure with a left ventricular ejection fraction of at least 45%, a BMI of at least 30 kg/m2, New York Heart Association class II-IV symptoms, and a Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; a measure of heart failure-related symptoms and physical limitations) of less than 90 points. In STEP-HFpEF, people with diabetes or glycated haemoglobin A1c concentrations of at least 6·5% were excluded, whereas for inclusion in STEP-HFpEF DM participants had to have been diagnosed with type 2 diabetes at least 90 days before screening and to have an HbA1c of 10% or lower. In both trials, participants were randomly assigned to either 2·4 mg semaglutide once weekly or matched placebo for 52 weeks. The dual primary endpoints were change from baseline to week 52 in KCCQ-CSS and bodyweight in all randomly assigned participants. Confirmatory secondary endpoints included change from baseline to week 52 in 6-min walk distance, a hierarchical composite endpoint (all-cause death, heart failure events, and differences in changes in KCCQ-CSS and 6-min walk distance); and C-reactive protein (CRP) concentrations. Heterogeneity in treatment effects was assessed across subgroups of interest. We assessed safety in all participants who received at least one dose of study drug. FINDINGS: Between March 19, 2021 and March 9, 2022, 529 people were randomly assigned in STEP-HFpEF, and between June 27, 2021 and Sept 2, 2022, 616 were randomly assigned in STEP-HFpEF DM. Overall, 1145 were included in our pooled analysis, 573 in the semaglutide group and 572 in the placebo group. Improvements in KCCQ-CSS and reductions in bodyweight between baseline and week 52 were significantly greater in the semaglutide group than in the placebo group (mean between-group difference for the change from baseline to week 52 in KCCQ-CSS 7·5 points [95% CI 5·3 to 9·8]; p<0·0001; mean between-group difference in bodyweight at week 52 -8·4% [-9·2 to -7·5]; p<0·0001). For the confirmatory secondary endpoints, 6-min walk distance (mean between-group difference at week 52 17·1 metres [9·2 to 25·0]) and the hierarchical composite endpoint (win ratio 1·65 [1·42 to 1·91]) were significantly improved, and CRP concentrations (treatment ratio 0·64 [0·56 to 0·72]) were significantly reduced, in the semaglutide group compared with the placebo group (p<0·0001 for all comparisons). For the dual primary endpoints, the efficacy of semaglutide was largely consistent across multiple subgroups, including those defined by age, race, sex, BMI, systolic blood pressure, baseline CRP, and left ventricular ejection fraction. 161 serious adverse events were reported in the semaglutide group compared with 301 in the placebo group. INTERPRETATION: In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide was superior to placebo in improving heart failure-related symptoms and physical limitations, and reducing bodyweight in participants with obesity-related heart failure with preserved ejection fraction. These effects were largely consistent across patient demographic and clinical characteristics. Semaglutide was well tolerated. FUNDING: Novo Nordisk.
Azienda Socio Sanitaria Territorial Papa Giovanni XXIII Bergamo Italy
Baylor Scott and White Research Institute Dallas TX USA
Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
Centro de Investigación Biomédica en Red Cardiovascular Valencia Spain
College of Health and Medicine Australian National University Canberra ACT Australia
Department of Cardiology Herlev Gentofte Hospital Hellerup Denmark
Department of Cardiovascular Disease Saint Luke's Mid America Heart Institute Kansas City MO USA
Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA
Department of Clinical Medicine University of Copenhagen Herlev Denmark
Department of General Internal Medicine 3 Kawasaki Medical School Okayama Japan
Department of Medicine University of Mississippi Jackson MS USA
Department of Noninvasive Cardiology Medical University of Lodz Lodz Poland
Diabetes Research Centre University of Leicester Leicester UK
Heart and Vascular Centre Semmelweis University Budapest Hungary
Hospital Clínico Universitario de Valencia INCLIVA Universidad de Valencia Valencia Spain
Institute for Clinical and Experimental Medicine IKEM Prague Czech Republic
Instituto de Cardiologia J F Cabral Corrientes Argentina
Max Super Speciality Hospital Saket New Delhi India
Medical University of Graz Graz Austria
National Institute for Health and Care Research Leicester Biomedical Research Centre Leicester UK
School of Cardiovascular and Metabolic Health University of Glasgow Glasgow UK
Section of Cardiology Department of Medicine Sahlgrenska University Hospital Ostra Gothenburg Sweden
University of Missouri Kansas City School of Medicine Kansas City MO USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014245
- 003
- CZ-PrNML
- 005
- 20240905134025.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(24)00469-0 $2 doi
- 035 __
- $a (PubMed)38599221
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Butler, Javed $u Baylor Scott & White Research Institute, Dallas, TX, USA; Department of Medicine, University of Mississippi, Jackson, MS, USA
- 245 10
- $a Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials / $c J. Butler, SJ. Shah, MC. Petrie, BA. Borlaug, SZ. Abildstrøm, MJ. Davies, GK. Hovingh, DW. Kitzman, DV. Møller, S. Verma, MN. Einfeldt, ML. Lindegaard, S. Rasmussen, W. Abhayaratna, FZ. Ahmed, T. Ben-Gal, V. Chopra, JA. Ezekowitz, M. Fu, H. Ito, M. Lelonek, V. Melenovský, B. Merkely, J. Núñez, E. Perna, M. Schou, M. Senni, K. Sharma, P. van der Meer, D. Von Lewinski, D. Wolf, MN. Kosiborod, STEP-HFpEF Trial Committees and Investigators
- 520 9_
- $a BACKGROUND: In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction. In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, we aimed to provide a more definitive assessment of the effects of semaglutide across a range of outcomes and to test whether these effects were consistent across key patient subgroups. METHODS: We conducted a prespecified pooled analysis of individual patient data from STEP-HFpEF and STEP-HFpEF DM, randomised, double-blind, placebo-controlled trials at 129 clinical research sites in 18 countries. In both trials, eligible participants were aged 18 years or older, had heart failure with a left ventricular ejection fraction of at least 45%, a BMI of at least 30 kg/m2, New York Heart Association class II-IV symptoms, and a Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; a measure of heart failure-related symptoms and physical limitations) of less than 90 points. In STEP-HFpEF, people with diabetes or glycated haemoglobin A1c concentrations of at least 6·5% were excluded, whereas for inclusion in STEP-HFpEF DM participants had to have been diagnosed with type 2 diabetes at least 90 days before screening and to have an HbA1c of 10% or lower. In both trials, participants were randomly assigned to either 2·4 mg semaglutide once weekly or matched placebo for 52 weeks. The dual primary endpoints were change from baseline to week 52 in KCCQ-CSS and bodyweight in all randomly assigned participants. Confirmatory secondary endpoints included change from baseline to week 52 in 6-min walk distance, a hierarchical composite endpoint (all-cause death, heart failure events, and differences in changes in KCCQ-CSS and 6-min walk distance); and C-reactive protein (CRP) concentrations. Heterogeneity in treatment effects was assessed across subgroups of interest. We assessed safety in all participants who received at least one dose of study drug. FINDINGS: Between March 19, 2021 and March 9, 2022, 529 people were randomly assigned in STEP-HFpEF, and between June 27, 2021 and Sept 2, 2022, 616 were randomly assigned in STEP-HFpEF DM. Overall, 1145 were included in our pooled analysis, 573 in the semaglutide group and 572 in the placebo group. Improvements in KCCQ-CSS and reductions in bodyweight between baseline and week 52 were significantly greater in the semaglutide group than in the placebo group (mean between-group difference for the change from baseline to week 52 in KCCQ-CSS 7·5 points [95% CI 5·3 to 9·8]; p<0·0001; mean between-group difference in bodyweight at week 52 -8·4% [-9·2 to -7·5]; p<0·0001). For the confirmatory secondary endpoints, 6-min walk distance (mean between-group difference at week 52 17·1 metres [9·2 to 25·0]) and the hierarchical composite endpoint (win ratio 1·65 [1·42 to 1·91]) were significantly improved, and CRP concentrations (treatment ratio 0·64 [0·56 to 0·72]) were significantly reduced, in the semaglutide group compared with the placebo group (p<0·0001 for all comparisons). For the dual primary endpoints, the efficacy of semaglutide was largely consistent across multiple subgroups, including those defined by age, race, sex, BMI, systolic blood pressure, baseline CRP, and left ventricular ejection fraction. 161 serious adverse events were reported in the semaglutide group compared with 301 in the placebo group. INTERPRETATION: In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide was superior to placebo in improving heart failure-related symptoms and physical limitations, and reducing bodyweight in participants with obesity-related heart failure with preserved ejection fraction. These effects were largely consistent across patient demographic and clinical characteristics. Semaglutide was well tolerated. FUNDING: Novo Nordisk.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a srdeční selhání $x farmakoterapie $7 D006333
- 650 12
- $a glukagonu podobné peptidy $x terapeutické užití $x aplikace a dávkování $7 D004763
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a tepový objem $x účinky léků $7 D013318
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 12
- $a obezita $x komplikace $x farmakoterapie $7 D009765
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Shah, Sanjiv J $u Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 700 1_
- $a Petrie, Mark C $u School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
- 700 1_
- $a Borlaug, Barry A $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Abildstrøm, Steen Z $u Novo Nordisk, Søborg, Denmark
- 700 1_
- $a Davies, Melanie J $u Diabetes Research Centre, University of Leicester, Leicester, UK; National Institute for Health and Care Research Leicester Biomedical Research Centre, Leicester, UK
- 700 1_
- $a Hovingh, G Kees $u Novo Nordisk, Søborg, Denmark
- 700 1_
- $a Kitzman, Dalane W $u Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, USA
- 700 1_
- $a Møller, Daniél Vega $u Novo Nordisk, Søborg, Denmark
- 700 1_
- $a Verma, Subodh $u Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Einfeldt, Mette Nygaard $u Novo Nordisk, Søborg, Denmark
- 700 1_
- $a Lindegaard, Marie L $u Novo Nordisk, Søborg, Denmark
- 700 1_
- $a Rasmussen, Søren $u Novo Nordisk, Søborg, Denmark
- 700 1_
- $a Abhayaratna, Walter $u College of Health and Medicine, Australian National University, Canberra, ACT, Australia
- 700 1_
- $a Ahmed, Fozia Z $u Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
- 700 1_
- $a Ben-Gal, Tuvia $u Heart Failure Unit, Department of Cardiology, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Chopra, Vijay $u Max Super Speciality Hospital, Saket, New Delhi, India
- 700 1_
- $a Ezekowitz, Justin A $u Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada
- 700 1_
- $a Fu, Michael $u Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden
- 700 1_
- $a Ito, Hiroshi $u Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan
- 700 1_
- $a Lelonek, Małgorzata $u Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Melenovský, Vojtěch $u Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic
- 700 1_
- $a Merkely, Bela $u Heart and Vascular Centre, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Núñez, Julio $u Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red Cardiovascular, Valencia, Spain
- 700 1_
- $a Perna, Eduardo $u Instituto de Cardiologia J F Cabral, Corrientes, Argentina
- 700 1_
- $a Schou, Morten $u Department of Cardiology, Herlev-Gentofte Hospital, Hellerup, Denmark; Department of Clinical Medicine, University of Copenhagen, Herlev, Denmark
- 700 1_
- $a Senni, Michele $u Azienda Socio Sanitaria Territorial Papa Giovanni XXIII, Bergamo, Italy
- 700 1_
- $a Sharma, Kavita $u Heart Failure & Cardiac Transplantation, Johns Hopkins University Heart Failure with Preserved Ejection Fraction Program, Johns Hopkins Hospital, Baltimore, MD, USA
- 700 1_
- $a van der Meer, Peter $u Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- 700 1_
- $a Von Lewinski, Dirk $u Medical University of Graz, Graz, Austria
- 700 1_
- $a Wolf, Dennis $u Cardiology and Angiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- 700 1_
- $a Kosiborod, Mikhail N $u Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address: mkosiborod@saint-lukes.org
- 710 2_
- $a STEP-HFpEF Trial Committees and Investigators
- 773 0_
- $w MED00010161 $t Lancet $x 1474-547X $g Roč. 403, č. 10437 (2024), s. 1635-1648
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38599221 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134019 $b ABA008
- 999 __
- $a ok $b bmc $g 2143812 $s 1226111
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 403 $c 10437 $d 1635-1648 $e 20240407 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- GRA __
- $a R01 HL140731 $p NHLBI NIH HHS $2 United States
- GRA __
- $a R01 HL127028 $p NHLBI NIH HHS $2 United States
- GRA __
- $a R01 HL107577 $p NHLBI NIH HHS $2 United States
- GRA __
- $a R01 HL149423 $p NHLBI NIH HHS $2 United States
- GRA __
- $a U54 HL160273 $p NHLBI NIH HHS $2 United States
- LZP __
- $a Pubmed-20240725
